Notice2022-15910
Government-Owned Inventions; Availability for Licensing
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 26, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 142 (Tuesday, July 26, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 142 (Tuesday, July 26, 2022)]
[Notices]
[Page 44413]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-15910]
[[Page 44413]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Theodoric Mattes at 240-627-3827, or
<a href="/cdn-cgi/l/email-protection#8cf8e4e9e3e8e3fee5efa2e1edf8f8e9ffcce2e5e4a2ebe3fa"><span class="__cf_email__" data-cfemail="c6b2aea3a9a2a9b4afa5e8aba7b2b2a3b586a8afaee8a1a9b0">[email protected]</span></a>. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Lymphatic Filariasis Biomarkers for Detection and Surveillance
Description of Technology:
Lymphatic filariasis (elephantiasis; LF) is a neglected tropical
disease that affects over 120 million people throughout the tropics and
subtropics of Asia, Africa, the Western Pacific, and parts of the
Caribbean and South America. LF results from infection with the
filarial parasites Wuchereria bancrofti or Brugia malayi. Current
methods of confirming active infection by W. bancrofti or B. malayi
include microscopy and immunoassays using serum/plasma extracted from
the patient. However, the sensitivity of microscopy detection varies
among patients, and immunoassays show cross-reactivity with antibodies
directed towards other parasites, such as Onchocerca volvulus or Loa
loa whose geographic distribution can overlap with the LF-causing
filarial parasites.
This new technology addresses the limitations of cross-reactivity
through the detection of a single antigen, Wb5B, selected due to a lack
of homologs in other filarial parasites that infect humans. Preliminary
data indicates that Wb5B is immunogenic, highly specific (>99%), and
accurate (>90%) for the detection of W. bancrofti infection in sera
from humans and other mammalian sources. The antigen can be isolated in
soluble form for integration in a variety of diagnostic assay formats.
The subject technology, including the antigen sequence as well as
plasmids enabling bacterial, insect, and mammalian cell expression, is
available for licensing for commercial development in accordance with
35 U.S.C. 209 and 37 CFR part 404, as well as for further development
and evaluation under a research collaboration.
There may be the potential to combine this technology with another
NIAID-developed biomarker technology (Wb123, available for licensing;
see HHS Ref. No. E-281-2010-0, ``Diagnostic Assays and Methods of Use
for Detection of Filarial Infection'') for the development of a
multiplex assay for detection of active W. bancrofti infection for
diagnostic or surveillance purposes.
Potential Commercial Applications:
<bullet> Diagnostics for W. bancrofti infection
<bullet> Surveillance for W. bancrofti prevalence
Competitive Advantages:
<bullet> Increased specificity compared to available diagnostics
<bullet> Differentiation from other parasites with similar geographic
footprints
Development Stage: Pre-Clinical.
Inventors: Thomas B. Nutman, Sasisekhar Bennuru, both of NIAID.
Intellectual Property: U.S. Provisional Patent Application Serial
No. 63/347,794, filed June 1, 2022.
Related Inventions: Diagnostic Assays and Methods of Use for
Detection of Filarial Infection (HHS Reference No. E-281-2010-0).
Licensing Contact: To license this technology, please contact
Theodoric Mattes at 240-627-3827, or <a href="/cdn-cgi/l/email-protection#42362a272d262d302b216c2f2336362731022c2b2a6c252d34"><span class="__cf_email__" data-cfemail="fa8e929f959e95889399d4979b8e8e9f89ba949392d49d958c">[email protected]</span></a>., and
reference E-093-2022-0.
Collaborative Research Opportunity: The National Institute of
Allergy and Infectious Diseases is seeking statements of capability or
interest from parties interested in collaborative research to further
develop, evaluate, or commercialize this technology. For collaboration
opportunities, please contact Theodoric Mattes at 240-627-3827, or
<a href="/cdn-cgi/l/email-protection#196d717c767d766b707a3774786d6d7c6a59777071377e766f"><span class="__cf_email__" data-cfemail="cfbba7aaa0aba0bda6ace1a2aebbbbaabc8fa1a6a7e1a8a0b9">[email protected]</span></a>.
Dated: July 14, 2022.
Surekha Vathyam,
Deputy Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2022-15910 Filed 7-25-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 26, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.